Obesity

It's a Quadruple-Victory for Pets Global (Malaysia) Sdn Bhd in the 2023 Natural Health Readers' Choice Awards

Retrieved on: 
Wednesday, March 6, 2024

Four revered titles covering pet care products picked up in Natural Health Readers' Choice Awards 2023

Key Points: 
  • A first-time winner in the much-anticipated annual event, Pets Global is an independently owned, holistic wellness company which was established based on a deep-rooted concern for the welfare of animals.
  • As such, the company exercises its rights to create and produce the highest quality foods and pet-care products for our furry companions, namely cats and dogs.
  • Eric Lum, Sales & Marketing Manager of Pets Global (Malaysia) Sdn Bhd, expressed his gratitude and appreciation for the three Awards picked up by Fussie Cat.
  • Also, we always give our best in ensuring quality for all our dry food products, as with all other products from us."

Metabolica Health Completes Amalgamation with Big Fish and Announces Non-Brokered Private Placement

Retrieved on: 
Monday, February 26, 2024

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ("Metabolica" or the "Company") a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the "Amalgamation Agreement") with Big Fish Acquisition Corp. ("Big Fish"), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ("Metabolica Health"), continuing the business of Metabolica.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Metabolica Health Inc. ("Metabolica" or the "Company") a pioneering biotechnology firm at the forefront of diabetes and obesity treatment research, is pleased to announce the completion of its amalgamation (the "Amalgamation Agreement") with Big Fish Acquisition Corp. ("Big Fish"), effective on January 1, 2024, with the resulting amalgamated company, named Metabolica Health Inc. ("Metabolica Health"), continuing the business of Metabolica.
  • Pursuant to the terms of the Amalgamation Agreement dated October 30, 2023, Big Fish amalgamated with Metabolica to form Metabolica Health, and the issued shares of each of Metabolica and Big Fish were exchanged for shares of Metabolica Health or otherwise dealt with as follows: (a) each Class A Common share of Metabolica was exchanged for 22.213 common shares of Metabolica Health; and (b) each common share of Big Fish was exchanged for one-half of one common share of Metabolica Health.
  • Following the successful amalgamation transaction (the "Transaction"), Metabolica Health is pleased to announce that it is arranging a non-brokered private placement (the "Offering") of up to 2,500,000 Units, at a price of $0.40 per Unit, for gross proceeds of up to $1,000,000.
  • Furthermore, Metabolica Health is announcing the appointment of Mr. Scott Jardin, CPA, CGA, as the company's Chief Financial Officer.

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

Retrieved on: 
Monday, March 11, 2024

FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).

Key Points: 
  • FOSTER CITY, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).
  • “CML is a serious leukemia that requires chronic, life-long treatment,” said Emil Kuriakose, MD, chief medical officer of Terns.
  • Orphan drug designation for TERN-701 underscores the FDA’s recognition of the unmet need for people living with CML and Terns’ commitment to developing new treatment options.”
    FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States.
  • Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity.

Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor

Retrieved on: 
Monday, March 11, 2024

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced a novel development candidate, MRT-8102, a potent, highly selective and orally bioavailable NIMA related kinase 7 (NEK7)-directed MGD. MRT-8102 is expected to be developed for the treatment of inflammatory diseases driven by interleukin-1β (IL-1β) and the NLRP3 inflammasome, which are critical elements of the inflammatory process. This is the first development candidate to be declared from the Company’s NEK7 development program.

Key Points: 
  • This is the first development candidate to be declared from the Company’s NEK7 development program.
  • “In preclinical non-human primate studies, MRT-8102 has demonstrated potent and selective degradation of NEK7, reducing downstream IL-1β.
  • We believe MRT-8102 has the potential to be developed in multiple inflammatory diseases, including gout, pericarditis and other cardiovascular diseases.
  • IND-enabling studies are underway, and we plan to file our first IND for the program in the first quarter of 2025.

Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event

Retrieved on: 
Monday, March 11, 2024

SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, will provide clinical and pipeline updates today during its virtual investor event.

Key Points: 
  • We believe these data support the potential for VTX3232 to emerge as a best-in-class CNS-penetrant NLRP3 inhibitor for the treatment of neuroinflammatory diseases.
  • We believe these data establish compelling clinical proof of concept for our peripheral NLRP3 inhibitor VTX2735.
  • At our virtual investor event, we will present data from the ongoing Phase 2 open-label extension.
  • Ventyx will host a virtual investor event today, Monday, March 11, 2024 from 11:00AM to 12:30PM ET.

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024

ET

Key Points: 
  • ET
    THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended December 31, 2023 and provided an update on key corporate milestones.
  • “2023 was a pivotal year for Lexicon,” said Lonnel Coats, Lexicon’s chief executive officer.
  • Unless otherwise stated, all comparisons are for the fourth quarter and full year of 2023 compared to the fourth quarter and full year of 2022.
  • Revenues: Revenues for the fourth quarter and full year of 2023 were $0.7 million and $1.2 million, respectively, primarily from the commercialization of INPEFA.

Meat is Eating Up The Planet: US Reaches 'Meat Exhaustion Day' Today

Retrieved on: 
Friday, March 8, 2024

Eating meat beyond the recommended amount not only has huge human health risks, the industry also causes massive suffering to animals, with 83.3 billion being slaughtered for meat every year.

Key Points: 
  • Eating meat beyond the recommended amount not only has huge human health risks, the industry also causes massive suffering to animals, with 83.3 billion being slaughtered for meat every year.
  • On average, a person in the US consumes almost 3.6 pounds of meat per week.
  • This is the equivalent amount of meat in 14 burgers per person per week, making Americans the biggest consumers of meat in the world.
  • Global meat consumption is eating up the planet, causing animal and human suffering,” says FOUR PAWS CEO and President Josef Pfabigan.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Friday, March 8, 2024

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.

Key Points: 
  • “In 2023 we demonstrated clear proof-of-concept with our lead GLP-1 receptor agonist, GSBR-1290, for obesity and type 2 diabetes.
  • This study is fully enrolled and data are expected in the latter half of the second quarter of 2024.
  • The Company plans to initiate a global Phase 2b obesity study of GSBR-1290 in the fourth quarter of 2024.
  • Net Loss: Net loss for the fourth quarter of 2023 totaled $24.5, with non-cash stock-based compensation expense of $2.1 million, compared to $11.9 million for the fourth quarter of 2022 with non-cash stock-based compensation expense of $0.6 million.

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Retrieved on: 
Thursday, March 7, 2024

SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease, today announced publication of results in Clinical Gastroenterology and Hepatology from an expansion cohort (Cohort D, N=31) of the Phase 2b SYMMETRY study.
  • Tolerability of EFX on top of GLP-1RA (N=21 patients) was generally comparable to GLP-1RA alone (placebo, N=10).
  • The most frequent adverse events for EFX-treated patients were grade 1 or 2 gastrointestinal events (diarrhea, nausea, and increased appetite).
  • Patients treated with EFX plus GLP-1RA showed a similar mean weight loss from baseline relative to patients treated with GLP-1RA alone.